amyloidosis

PD146176 (NSC-168807) is an inhibitor of 15-Lipoxygenase (15-LO) , it inhibits rabbit reticulocyte 15-LO with Ki of 197 nM and IC50 of 0.54 μM. PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice.

Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Eprodisate disodium (NC-503) is a negatively charged sulfonated inhibitor of fibrillogenesis, used in the treatment of amyloid A (AA) amyloidosis.

IFB-088 acetate, a benzyl guanidine derivative, is used to treat diseases and cancers associated with the PPP1R15A pathway and associated with protein misfolding stress, Examples include tau disease, synaptic riboprotein disease, polyglutamine and polyalanine diseases, leukodystrophy, cystic fibrosis, multiple sclerosis, lysosome storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardiovascular diseases, osteoporosis, neurological trauma, and more.

amyloid P-IN-1 can be used in studies about diseases with depletion of serum amyloid P components such as Alzheimer's disease, amyloidosis, osteoarthritis, and type 2 diabetes mellitus.

3-Demethylthiocolchicine, a colchicine analog, exhibits broad-spectrum antitumor activity and shares similar properties and activities with colchicine in inhibiting casein-induced amyloidosis, microtubule binding, and anti-inflammatory effects. Notably, it has significantly lower toxicity compared to colchicine.

(9R)-RO7185876 (Compound example 16) is a γ-secretase inhibitor. It reduces the secretion of Αβ42. This compound can be employed in the research of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, multi-infarct dementia, senile dementia, or Down syndrome.

Revusiran (ALN-TTRSC) is a first-generation short interfering RNA (siRNA) that specifically targets transthyretin (TTR) mRNA and is utilized in TTR-mediated amyloidosis research.

Eprodisate is a novel compound specifically developed to disrupt the interactions between amyloidogenic proteins and glycosaminoglycans, effectively impeding the polymerization of amyloid fibrils and their deposition in tissues. This compound shows potential for delaying the advancement of AA amyloidosis-related renal disease and could apply to various forms of amyloidosis.

Acoramidis hydrochloride (Alxn2060 hydrochloride) is an orally active and selective kinetic stabilizer of WT and V122I- TTR (transthyretin) . Acoramidis hydrochloride is used in the study for transthyretin amyloidosis.

Poloxamer 188 is a nonionic triblock copolymer surfactant and bioactive excipient used as a medical excipient to exacerbate cerebral amyloidosis, presynaptic dystrophy, and pathogenic microglial cell activation in 5XFAD mice.

Birtamimab (NEOD001) is a monoclonal antibody selectively targeting and depleting amyloid protein, used in research on light chain amyloidosis.

Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal immunoglobulin G1 (IgG1) antibody specifically targeting the serum amyloid P component (SAP), a protein universally found in all types of amyloid deposits, and it possesses potential anti-amyloid activity by triggering an immunotherapeutic mechanism for the clearance of amyloid fibrils through macrophage-mediated phagocytosis, which can be applied in the research of amyloid light-chain (AL) amyloidosis and other systemic amyloid diseases.

Anti-amyloid agent-1 is a potent compound that inhibits amyloid aggregation, offering a promising approach for research into the treatment of amyloidosis [1].

PITB, a selective and orally active transthyretin (TTR) aggregation inhibitor, is utilized in transthyretin amyloidosis (ATTR) disease research [1].

WAY-612453 is an active compound utilized in researching amyloid diseases and synucleinopathies.

Anselamimab is a humanized IgG1κ monoclonal antibody targeting serum amyloid A1 (SAA1). It removes amyloid deposits by specifically binding to amyloid fibrils and triggering phagocytosis by macrophages and neutrophils.Anselamimab was used as an APP(β-amyloid A4 Protein Precursor ) inhibitor in the clinical phase for the treatment of light chain (AL) amyloidosis.

Transthyretin-IN-2 (Compound 36), a transthyretin (TTR) amyloidosis inhibitor, exhibits IC50 and pIC50 values of 1.31 μM and 5.88 μM, respectively. It is useful for researching TTR amyloidosis diseases [1].

AG-10 (Acoramidis) is an orally active and selective kinetic stabilizer of TTR (transthyretin). AG-10 exhibits activity for WT and V122I-TTR. AG-10 is used in the study of transthyretin amyloidosis.

Cliramitug is a monoclonal antibody that targets human transthyretin protein (TTR). By binding to TTR, Cliramitug inhibits its amyloid formation process and exhibits activity that prevents amyloid deposition. Cliramitug holds potential for research in transthyretin amyloidosis-related diseases, including certain neurological and cardiovascular conditions.

Tauroursodeoxycholic Acid-d4 Sodium Salt is a deuterated compound of Tauroursodeoxycholic Acid Sodium Salt. Tauroursodeoxycholic Acid Sodium Salt has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Tauroursodeoxycholic-2,2,3,4,4-d5 Acid is a deuterated compound of Tauroursodeoxycholic Acid. Tauroursodeoxycholic Acid has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Tauroursodeoxycholic-d4 Acid is a deuterated compound of Tauroursodeoxycholic Acid. Tauroursodeoxycholic Acid has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

ABBV-383 (ABBV-383), a BCMA × CD3 bispecific T-cell engager (BiTE), targets and inhibits the B-cell maturation antigen (BCMA) while concurrently activating the T-cell surface glycoprotein CD3 complex. This compound is utilized in research focused on multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases.